Featured
Lead report
Celcuity Targets Q3 2026 for REVTORPYK Launch and sNDA Submission, Accelerating Commercialization
Celcuity plans to ship REVTORPYK and file its sNDA by Q3 2026, backed by positive clinical data and commercial readiness. The market watches its execution as it transitions from clinical to commercial stage.
Immunovant Q1 FY2027 Earnings Preview: IMVT-1402 Progress and Cash Runway in Focus
Immunovant is set to report Q1 FY2027 results, with investors eyeing IMVT-1402 clinical updates, batoclimab's fate, and cash burn. Pipeline catalysts and valuation risks are analyzed.
AC Immune H1 Results: Alzheimer's Vaccine Data on the Horizon, Cash Runway Secured Through 2027
AC Immune reported H1 2025 results with increased R&D spending and a cash runway into 2027. Key catalyst is the upcoming Phase IIb data for ACI-24.060, with partnerships with Roche and Lilly advancing.
More Related Articles
Summit Therapeutics Announces FDA PDUFA Date for Ivonescimab and HARMONi-3 Data Timeline
Summit Therapeutics sets FDA PDUFA target date for ivonescimab on November 14 and plans HARMONi-3 PFS data readout in H2 2026. Analysis of regulatory decisions and clinical progress impacts on stock and industry landscape.
Taysha Gene Therapies Plunges on $200M Stock Offering at $6 Per Share
Taysha Gene Therapies announced a $200 million public offering at $6 per share, causing a sharp after-hours selloff. The article analyzes the dilutive financing, pipeline progress, and investor concerns.
Syntax Bio Closes $14.4M Series A, Adds New CBO and Board Members
Gene editing company Syntax Bio expands its Series A to $14.4 million, appoints a new Chief Business Officer and two independent directors. Funds will advance metabolic disease gene therapy pipeline and technology platform.
Biogen Acquires RayThera for Up to $1 Billion: Strategic Expansion in Neuroscience
Biogen has agreed to acquire privately held biotech RayThera for up to $1 billion, gaining a preclinical candidate targeting Alzheimer's and other neurodegenerative diseases. The deal underscores Biogen's deepening commitment to neuroscience.
Moderna Evaluates German Production Facilities as BioNTech Shuts Down Plants: mRNA Vaccine Industry in Flux
Moderna is reportedly assessing the acquisition of production facilities in Germany, while BioNTech plans to close some plants. This shift reflects post-pandemic capacity rebalancing in the mRNA vaccine sector, offering insights for U.S. biotech investment strategies.
This Week's Blockbuster Deals: GSK, Incyte, Ingredion, OpenAI Lead US Stock Market Trends
A deep dive into key US stock market moves this week, including GSK's consumer health divestiture, Incyte's acquisition of MorphoSys, Ingredion's South American business sale, and OpenAI's $40 billion funding round, along with updates on Tesla, Apple, and Amazon.
Sanofi's Tzield Receives FDA Approval for Stage 3 Type 1 Diabetes Treatment, Boosting US Stock
Sanofi announced FDA approval of Tzield for stage 3 type 1 diabetes, filling an immunomodulatory therapy gap. Market response is positive, with analysts projecting peak sales of $2-3 billion, strengthening the company's metabolic disease pipeline.
Aethlon Tumor Trial Expands to 3-6 Patients: Hemopurifier Clinical Progress Analysis
Aethlon Medical announces expansion of Hemopurifier tumor trial Cohort 3 to 3-6 patients, focusing on exosome clearance combined with immunotherapy. This article analyzes the technology, financial background, competitive landscape, and key investor considerations.
Exicure Receives Nasdaq Deficiency Notice for Shareholders' Equity, Faces Delisting Risk
Biotech firm Exicure gets a Nasdaq warning for shareholders' equity falling below $2.5 million, with 45 days to submit a compliance plan. Understand the company's background, market reaction, and potential implications.
Parabilis Medicines IPO Priced at $19 Per Share, Upsized Offering
Biotech firm Parabilis Medicines completes IPO at $19 per share, upsizing to 12 million shares and raising approximately $228 million, as market focuses on its precision medicine pipeline progress.
